Nanobiotix Files Routine 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Sep 12, 2025 · CIK: 1760854
Sentiment: neutral
Topics: sec-filing, routine-report, foreign-private-issuer
TL;DR
Nanobiotix filed a standard 6-K, no major news here.
AI Summary
Nanobiotix S.A. filed a Form 6-K on September 12, 2025, to report information for the month of September 2025. The company, based in Paris, France, is a pharmaceutical preparations company and files its annual reports under Form 20-F. This filing does not appear to contain specific financial figures or significant operational updates beyond its routine reporting status.
Why It Matters
This filing indicates Nanobiotix is fulfilling its regular reporting obligations with the SEC, which is standard for publicly traded foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material information or financial disclosures.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the 6-K report
- 001-39777 (other) — SEC File Number for Nanobiotix S.A.
- 20-F (document) — Form under which Nanobiotix files annual reports
- 60 Rue de Wattignies, 75012 Paris, France (address) — Principal executive office address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What is Nanobiotix S.A.'s primary business sector?
Nanobiotix S.A. is classified under the Pharmaceutical Preparations sector, with SIC code 2834.
When does Nanobiotix S.A. file its annual reports?
Nanobiotix S.A. files its annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of September 12, 2025.
Does this filing indicate any new financial results or operational updates?
No, this Form 6-K appears to be a routine filing and does not contain specific financial figures or significant operational updates beyond its reporting status.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-09-12 16:15:04
Filing Documents
- f6k_091225.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-005887.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: September 12, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer